Pediatric Cancer Advocates Meet With National Cancer Institute Leadership To Advance Research

Max Wallace, CEO of Accelerate Brain Cancer Cure, is the chair of the NCI’s Director’s Consumer Liaison Group (DCLG) – a group of patient advocacy leaders who provide the Director of the NCI with critical perspectives to improve outcomes for patients with all types of cancers.

The group met in February at the NCI campus in Bethesda, Maryland.  The day-long session focused on the barriers that are impeding the development of effective treatments for children with cancer and how advocacy groups could help advance research.  Experts from the NCI, FDA, the Children's Hospital of Philadelphia and a host of pediatric cancer advocacy organizations participated in the meeting.

This area is of particular interest for ABC2 because of the organization's recent support of the first pediatric brain tumor immunotherapy trial at University of Florida. Dr. Duane Mitchell is the principal investigator.  Mitchell and his team of 10 researchers are using new approaches to treat tumors that use a patient’s immune system to combat cancer alongside conventional treatments, such as surgery, radiation and chemotherapy. 

Click HERE for a copy of the DCLG agenda on "The Barriers to Drug Development in Pediatric Cancer Research".  Click HERE for videocast of the meeting.

The first DCLG meeting under Wallace's leadership was in December 2013.  The group addressed the issue of "The Future of Big Data To Improve Research."  Click HERE for the agenda of that session.

DCLG meetings are generally held on a quarterly basis and are always open to the public.  Click HERE to learn more about attending an upcoming meeting. 


Main Image Credit: 
Maureen Lilly, Children's Cause for Cancer Advocacy and Max Wallace, Accelerate Brain Cancer Cure
Share |
November 18, 2014 12:33 PM
Accelerate Brain Cancer Cure funded Duke University's early work on the vaccine.
November 7, 2014 02:28 PM
Proceeds to benefit Accelerate Brain Cancer Cure.
November 6, 2014 02:51 PM
Second Brain Tumor Clinical Trial Endpoints Workshop identified steps needed to include measures of patient signs, symptoms, and function as part of evaluation of therapy benefit.

Join us in our fight for a cure!